联影医疗（688271.SH） 国内市场稳健增长，海外市场表现亮眼，AI 赋能战略坚定推进 证券研究报告 | 半年报点评 gszqdatemark 2025 09 04 年 月 日 联影医疗发布 2025 年半年度报告。2025H1 公司实现营业收入 60.16 亿元，同比增长 12.79%；归母净利润 9.98 亿元，同比增长 5.03%；扣非后归母净利润 9.66 亿元，同比增 长 21.01%。分季度看，2025Q2 实现营业收入 35.38 亿元，同比增长 18.60%；归母净利润 6.28 亿元，同比增长 6.99%；扣非后归母净利润 5.87 亿元，同比增长 17.96%。 观点：招采需求稳步复苏，设备与服务协同增长，MR、XR 等产品增长靓丽，重点产品线海 内外市场均有所突破。海外市场高速增长，高端市场与新兴市场均有所突破。AI 已赋能至 各产品线，助力产品力提升，国产医学影像龙头强者恒强。 招采需求逐步复苏，公司业绩稳健增长，服务业务表现亮眼。2025H1公司实现设备收入48.90 亿元（同比+7.61%），服务收入 8.16 亿元（同比+32.21%），随着招采活动稳步恢复，设备 与服务协同 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company has shown impressive growth in overseas business and has made significant breakthroughs in high-end products [5] - Revenue forecasts for 2025-2027 are projected at 126.04 billion, 151.57 billion, and 182.24 billion yuan, with year-on-year growth rates of 22.37%, 20.25%, and 20.24% respectively [6] - The net profit attributable to the parent company for the same period is expected to be 18.71 billion, 22.87 billion, and 27.87 billion yuan, with growth rates of 48.26%, 22.23%, and 21.85% respectively [6] Financial Performance Summary - In 2024, the company achieved a revenue of 103.00 billion yuan (down 9.73% year-on-year) and a net profit of 12.62 billion yuan (down 36.09% year-on-year) [8] - For Q1 2025, the company reported a revenue of 24.78 billion yuan (up 5.42% year-on-year) and a net profit of 3.70 billion yuan (up 1.87% year-on-year) [8] - The company's main business gross margin for 2024 was 49.40%, an increase of 1.85 percentage points year-on-year [8] Market Position and Product Development - The company has seen a steady increase in domestic market share, with a rise of over 3 percentage points, and a nearly 5 percentage point increase in high-end product market share [8] - The company launched over 140 innovative products by the end of 2024, with 49 products receiving FDA registration [8]